about
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP familyCardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complexJAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expressionFunctional murine interleukin 6 receptor with the intracisternal A particle gene product at its cytoplasmic domain. Its possible role in plasmacytomagenesisIL-6 Plays a Crucial Role in HBV InfectionDifferential role of gp130-dependent STAT and Ras signalling for haematopoiesis following bone-marrow transplantationHepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6Protein Kinase C δ: a Gatekeeper of Immune HomeostasisA prospective study of renal disease in patients with early rheumatoid arthritisActivation of interleukin-6 gene expression through the NF-kappa B transcription factorGene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent.Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.Lecithinization of IL-6 enhances its thrombopoietic activity in mice.Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathwayHuman IL6 enhances leptin action in mice.Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.Plasma cell generation from B-lymphocytes via CD27/CD70 interaction.Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance.Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells.In vivo regulation of Bcl6 and T follicular helper cell development.IL-6 transgenic mouse model for extraosseous plasmacytoma.TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis.Anti-interleukin 6 receptor antibody treatment in rheumatic disease.Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells.Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice.Self DNA from lymphocytes that have undergone activation-induced cell death enhances murine B cell proliferation and antibody production.gp130 at the nexus of inflammation, autoimmunity, and cancer.Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes.Separate checkpoints regulate splenic plasma cell accumulation and IgG autoantibody production in Lyn-deficient miceNatural IgM is produced by CD5- plasma cells that occupy a distinct survival niche in bone marrowA granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8.Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesSurvival and proliferation factors of normal and malignant plasma cells.CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
P2860
Q24310416-9958A4D4-959A-4272-86A9-9176D00725D6Q24316473-D5DDEC72-EE45-4C17-9282-F2B4AAC3CE11Q24316553-14183543-BB05-47A1-BC3F-407813C654E0Q24682989-3A01A14F-5445-46F6-8BF7-F10A6B8FE0F6Q26774879-47B23563-27E1-4492-B4F1-311A1E01E85DQ27300594-01B91806-4E6B-45A9-9AA0-34A4D4E4E3DCQ27472816-0BC7F0DE-BD8F-4306-B094-06797E1A3339Q27686992-2D485D2E-B073-4499-B30A-26430FDFE2F8Q28360066-0A3894D3-D478-4374-A0FD-9F7E5CFC7E04Q28646310-57F78CF4-B8DB-4C07-A517-7374DB446DDCQ30444311-432F6092-9A0C-4C7C-A1CE-DF0F4EA4A802Q30561836-B7BD777D-BA53-4941-965B-99C68C272920Q31893425-1A29FEEC-2562-4A0F-89A6-D348372F1B15Q33354120-D317834A-8070-4D3A-9881-54D4EE0D293FQ33499080-4E381CA0-C201-4983-9A60-823741E3A304Q33543136-1499F977-A7EE-4070-B74E-1968279C672CQ33628094-AC93E7F4-DD8C-45FD-B00F-924744403313Q33744245-4BCB3064-8AAC-4D2E-AE74-56685A965283Q33856322-BDDFE7BC-933D-4A28-BA32-58956D0CB653Q33863961-36971880-3FC0-463C-BB31-DD2D866A31AFQ33911359-EC0CC8A6-E133-4EE2-913C-64A1C2FD41BCQ33936471-F3F35EA5-9E72-4ED9-8ABD-95835478961FQ34009997-D3324B3E-0EFB-42F0-9337-E40119CA423EQ34020424-18358A69-609D-4703-8628-F1224EA9A156Q34071253-3B8A32F8-DB9E-44A7-80B3-6D9AB02470D8Q34154676-EB4D7B7E-7090-45C7-A7C3-C61DA6EFEED1Q34194873-29123113-795A-4B93-85F1-E60F6DC484CFQ34228814-4C702AE1-5325-4923-9BD2-40EFF46BB138Q34259037-925639A1-81F7-4BDD-AF6D-4DE96C3D0054Q34270015-BFD1CD43-FFF4-479C-A929-7D60E87C9A93Q34307379-D23B052F-9AF5-489C-9FBE-B8C020FC1D0AQ34378756-D9F7E1D2-DB81-49CF-AF2B-6AC84AF58D6EQ34440657-FAF2D6E9-8E7A-4A3D-94A4-328185F509B3Q34671298-1CED720C-778B-43E1-B8C8-02142FDD16AFQ34749203-084283F9-5CBC-4B72-8F8D-EBE57EE51ACEQ34947392-8D900371-6ADF-40C1-AECB-EFC22A4C3FFEQ35096472-1FB87182-5517-4DD0-B95D-8C906F274124Q35132241-5604461B-9D16-4B9D-A349-F9675B6DF8E3Q35211028-57CC0AD3-B11F-4627-AD7E-E293F063DD22Q35247381-71E660C5-3318-4505-B7D8-C2D44A90309C
P2860
description
1989 nî lūn-bûn
@nan
1989 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@ast
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@en
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@nl
type
label
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@ast
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@en
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@nl
prefLabel
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@ast
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@en
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@nl
P2093
P2860
P356
P1476
IgG1 plasmacytosis in interleukin 6 transgenic mice.
@en
P2093
Kishimoto T
Miyazaki J
Suematsu S
Yamamura K
P2860
P304
P356
10.1073/PNAS.86.19.7547
P407
P577
1989-10-01T00:00:00Z